PubMed COVID-19 Clinical Care

Immunity following infection and vaccination with the SARS-CoV-2 Omicron variant is poorly understood. The aim was to investigate immunity assessed with antibody response, neutralizing antibodies (NAbs), and IFN-γ release under different scenarios

No abstract

CONCLUSIONS: Women who gave birth in the first year of the COVID-19 pandemic and prior to the widespread availability of vaccines were particularly vulnerable to adverse perinatal outcomes, including stillbirth and postpartum depression

Understanding community members' knowledge of SARS-CoV-2 transmission and prevention is essential for directing public health interventions to reduce disease spread and improve vaccination coverage. Here, we describe knowledge of COVID-19

During the COVID-19 outbreak in 2020, public health measures (PHM) were implemented to prevent the spread of SARS-CoV-2. At university, we wondered whether health students would be more likely to comply with these safety measures against infectious

CONCLUSION: The second booster strategy was likely to be dominant in reducing the disease burden of the COVID-19 pandemic. Expanding the second booster strategy to ages 18-49 and 12-17 years would remain dominant due to their social contacts with the

CONCLUSIONS: Childhood adversity was significantly associated with COVID-19-related hospitalisation and COVID-19-related mortality after adjusting for sociodemographic and health confounders. Further research is needed to clarify the biological and

We studied 226 patients in Toyama Prefecture, notified with COVID-19 during the first wave between March 30 and May 18, 2020. Of the 226 patients, 22 (9.7%) died, of whom most (95%) were aged ≥65 years. A large cluster comprising 59 patients (41

The widespread use of medical face masks during the SARS-CoV-2 pandemic has significantly increased plastic waste, with a considerable proportion of these masks ending up in the environment. As these masks are transported through wind and surface

The percentage of trisulfide variants is a product quality metric that is monitored during the manufacture of monoclonal antibody (mAb)-based therapeutics. Results from earlier preclinical studies revealed that trisulfide linkages in mAbs are rapidly